<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>CytoCares | wechat-feeds</title><link>http://MzAxNjQ3NjI4MA.favicon.privacyhide.com/favicon.ico</link><description>为您传递细胞治疗相关行业信息与技术进展，共同促进国内免疫治疗技术发展与行业繁荣。</description><managingEditor> (hellodword)</managingEditor><pubDate>Wed, 17 Mar 2021 19:17:56 +0800</pubDate><image><url>http://MzAxNjQ3NjI4MA.favicon.privacyhide.com/favicon.ico</url><title>CytoCares | wechat-feeds</title><link>http://MzAxNjQ3NjI4MA.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>CAR T细胞生产中的问题和挑战</title><link>https://mp.weixin.qq.com/s/zftUvnvnwjvn7lWfAZiTFQ</link><description></description><content:encoded><![CDATA[CAR T细胞生产中的问题和挑战]]></content:encoded><pubDate>Wed, 17 Mar 2021 19:17:02 +0800</pubDate></item><item><title>抗体药物动态-20210317</title><link>https://mp.weixin.qq.com/s/02Ko6rph92wMT1fj5hmJ9Q</link><description></description><content:encoded><![CDATA[抗体药物动态-20210317]]></content:encoded><pubDate>Wed, 17 Mar 2021 19:17:02 +0800</pubDate></item><item><title>后PD-(L)1时代：开启第二波热潮的免疫新靶点</title><link>https://mp.weixin.qq.com/s/JXM6a7TNWqlH1P9218VhFA</link><description></description><content:encoded><![CDATA[后PD-(L)1时代：开启第二波热潮的免疫新靶点]]></content:encoded><pubDate>Tue, 16 Mar 2021 19:04:53 +0800</pubDate></item><item><title>抗体药物动态-20210315</title><link>https://mp.weixin.qq.com/s/bdu5WiogpQ0Zlwd_KP4tvw</link><description></description><content:encoded><![CDATA[抗体药物动态-20210315]]></content:encoded><pubDate>Mon, 15 Mar 2021 19:48:54 +0800</pubDate></item><item><title>抗体药物动态-20210311</title><link>https://mp.weixin.qq.com/s/Wow7ARrzj7pib1t4OlQhzg</link><description></description><content:encoded><![CDATA[抗体药物动态-20210311]]></content:encoded><pubDate>Thu, 11 Mar 2021 18:45:37 +0800</pubDate></item><item><title>Roche等开发SAR-T：2+1双抗作为活性和安全开关</title><link>https://mp.weixin.qq.com/s/RB5C3rPDhwVt7PaoGqii2w</link><description></description><content:encoded><![CDATA[Roche等开发SAR-T：2+1双抗作为活性和安全开关]]></content:encoded><pubDate>Wed, 10 Mar 2021 18:43:55 +0800</pubDate></item><item><title>抗体药物动态-20210310</title><link>https://mp.weixin.qq.com/s/DW6Sda_21IK4wuRK0CP3KQ</link><description></description><content:encoded><![CDATA[抗体药物动态-20210310]]></content:encoded><pubDate>Wed, 10 Mar 2021 18:43:55 +0800</pubDate></item><item><title>IL-12家族：风湿，肿瘤，功能各不同</title><link>https://mp.weixin.qq.com/s/kTyUqwB98c4t0JlLksabtA</link><description></description><content:encoded><![CDATA[IL-12家族：风湿，肿瘤，功能各不同]]></content:encoded><pubDate>Tue, 09 Mar 2021 17:58:17 +0800</pubDate></item><item><title>全能核酸酶，为生物制品规模化生产解决核酸残留困扰</title><link>https://mp.weixin.qq.com/s/0-YdJcwwvVOmg33oBbi7Jw</link><description></description><content:encoded><![CDATA[全能核酸酶，为生物制品规模化生产解决核酸残留困扰]]></content:encoded><pubDate>Mon, 08 Mar 2021 19:13:18 +0800</pubDate></item><item><title>抗体药物动态-20210308</title><link>https://mp.weixin.qq.com/s/Jnbste15LeXV5D50RUV9Kg</link><description></description><content:encoded><![CDATA[抗体药物动态-20210308]]></content:encoded><pubDate>Mon, 08 Mar 2021 19:13:18 +0800</pubDate></item><item><title>Moderna公布IL-12 mRNA肿瘤疫苗I期数据，联用Durvalumab效果可期</title><link>https://mp.weixin.qq.com/s/otdAYcav2O7EuQpMoVbV0g</link><description></description><content:encoded><![CDATA[Moderna公布IL-12 mRNA肿瘤疫苗I期数据，联用Durvalumab效果可期]]></content:encoded><pubDate>Fri, 05 Mar 2021 18:42:06 +0800</pubDate></item><item><title>类风湿性关节炎疾病进程的三个检查点</title><link>https://mp.weixin.qq.com/s/PeomC7n97tNOUyLepUOa3w</link><description></description><content:encoded><![CDATA[类风湿性关节炎疾病进程的三个检查点]]></content:encoded><pubDate>Thu, 04 Mar 2021 18:32:48 +0800</pubDate></item><item><title>抗体药物动态-20210304</title><link>https://mp.weixin.qq.com/s/yWc1h8ohYluQdtj6q1nkSg</link><description></description><content:encoded><![CDATA[抗体药物动态-20210304]]></content:encoded><pubDate>Thu, 04 Mar 2021 18:32:48 +0800</pubDate></item><item><title>CAR-T细胞治疗为什么用自己的细胞更好？《Nature》子刊最新研究给出答案</title><link>https://mp.weixin.qq.com/s/Ot2A3FcVBTjzK66KId3_ew</link><description></description><content:encoded><![CDATA[CAR-T细胞治疗为什么用自己的细胞更好？《Nature》子刊最新研究给出答案]]></content:encoded><pubDate>Wed, 03 Mar 2021 19:14:59 +0800</pubDate></item></channel></rss>